JP2021536249A5 - - Google Patents

Info

Publication number
JP2021536249A5
JP2021536249A5 JP2021512393A JP2021512393A JP2021536249A5 JP 2021536249 A5 JP2021536249 A5 JP 2021536249A5 JP 2021512393 A JP2021512393 A JP 2021512393A JP 2021512393 A JP2021512393 A JP 2021512393A JP 2021536249 A5 JP2021536249 A5 JP 2021536249A5
Authority
JP
Japan
Prior art keywords
modified
cell
cells
csr
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536249A (ja
JP7605735B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049816 external-priority patent/WO2020051374A1/en
Publication of JP2021536249A publication Critical patent/JP2021536249A/ja
Publication of JP2021536249A5 publication Critical patent/JP2021536249A5/ja
Priority to JP2024217381A priority Critical patent/JP2025028160A/ja
Application granted granted Critical
Publication of JP7605735B2 publication Critical patent/JP7605735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512393A 2018-09-05 2019-09-05 同種異系細胞組成物およびその使用方法 Active JP7605735B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024217381A JP2025028160A (ja) 2018-09-05 2024-12-12 同種異系細胞組成物およびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862727498P 2018-09-05 2018-09-05
US62/727,498 2018-09-05
US201862744073P 2018-10-10 2018-10-10
US62/744,073 2018-10-10
US201962815334P 2019-03-07 2019-03-07
US62/815,334 2019-03-07
US201962815880P 2019-03-08 2019-03-08
US62/815,880 2019-03-08
PCT/US2019/049816 WO2020051374A1 (en) 2018-09-05 2019-09-05 Allogeneic cell compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024217381A Division JP2025028160A (ja) 2018-09-05 2024-12-12 同種異系細胞組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021536249A JP2021536249A (ja) 2021-12-27
JP2021536249A5 true JP2021536249A5 (enExample) 2022-09-12
JP7605735B2 JP7605735B2 (ja) 2024-12-24

Family

ID=68136519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512393A Active JP7605735B2 (ja) 2018-09-05 2019-09-05 同種異系細胞組成物およびその使用方法
JP2024217381A Pending JP2025028160A (ja) 2018-09-05 2024-12-12 同種異系細胞組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024217381A Pending JP2025028160A (ja) 2018-09-05 2024-12-12 同種異系細胞組成物およびその使用方法

Country Status (8)

Country Link
US (1) US20220389077A1 (enExample)
EP (1) EP3847197A1 (enExample)
JP (2) JP7605735B2 (enExample)
KR (2) KR20260080518A (enExample)
CN (2) CN119119296A (enExample)
AU (1) AU2019335014B2 (enExample)
CA (1) CA3111384A1 (enExample)
WO (1) WO2020051374A1 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532987A (ja) * 2017-09-08 2020-11-19 ポセイダ セラピューティクス,インコーポレイティド キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法
US12173317B2 (en) 2018-03-28 2024-12-24 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector T cells
SG10201802979VA (en) * 2018-04-10 2019-11-28 Kah Meng Lim Immunological extract and method of production
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
EP3959305A1 (en) * 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
WO2021046261A1 (en) * 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
CN115315273A (zh) * 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
WO2021163191A1 (en) * 2020-02-10 2021-08-19 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
CN115515646A (zh) 2020-03-04 2022-12-23 波赛达治疗公司 用于治疗代谢性肝病的组合物和方法
US20230121433A1 (en) * 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
KR20210121585A (ko) * 2020-03-30 2021-10-08 한국세라믹기술원 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
EP4189072A4 (en) * 2020-07-29 2024-09-18 Eureka Therapeutics, Inc. T-CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
CN112375138B (zh) * 2020-11-13 2022-12-13 中元汇吉生物技术股份有限公司 一种重组载脂蛋白e和应用
CN112402592B (zh) * 2020-12-04 2023-06-02 中国人民解放军陆军军医大学 Spink7蛋白在制备促进过度炎症创面愈合的药物中的应用
CN112480242B (zh) * 2020-12-04 2023-06-06 中国人民解放军陆军军医大学 Spink7蛋白在制备预防和/或治疗溃疡性结肠炎的药物中的应用
EP4262840A4 (en) * 2020-12-18 2024-11-20 Cullinan Amber Corp. IMMUNOMODULATORY MOLECULES LOCALIZED IN BI-FUNCTIONAL LINEAR FUSION COLLAGEN AND THEIR METHODS
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
US20240139322A1 (en) * 2021-03-10 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
CN113249361A (zh) * 2021-03-29 2021-08-13 南京欧凯生物科技有限公司 基质金属蛋白酶及其制备方法
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
EP4082560B1 (en) * 2021-04-27 2025-02-26 Academia Sinica Prap1 polypeptide for use in treating hypertriglyceridemia
CN113481185B (zh) * 2021-08-05 2022-12-02 云南师范大学 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用
CN113846070B (zh) * 2021-10-18 2023-05-16 翌圣生物科技(上海)股份有限公司 高活性的mTET2酶突变体、其编码DNA及其应用
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
CN113957075B (zh) * 2021-11-22 2023-04-07 百世诺(北京)医学检验实验室有限公司 突变的遗传性心律失常基因及其应用
CN116178562A (zh) * 2021-11-29 2023-05-30 四川大学华西医院 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用
WO2023098729A1 (en) * 2021-11-30 2023-06-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
CN114539376B (zh) * 2022-01-17 2023-06-13 中国水产科学研究院南海水产研究所 拟穴青蟹生物标记物cyp2基因及其在制备病理检测试剂中的应用
CN114487448B (zh) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
CN114137231B (zh) * 2022-01-29 2022-04-29 北京大有天弘科技有限公司 一种血型不规则抗体的检测试剂盒及其应用
WO2023151620A1 (zh) * 2022-02-09 2023-08-17 恺兴生命科技(上海)有限公司 用于细胞免疫学的组合物和方法
CN114646764B (zh) * 2022-04-08 2024-11-29 华南农业大学 一种arhgap35蛋白在猪x和y精子鉴定或分离中的应用
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN114958862B (zh) * 2022-05-23 2023-12-08 郑州伊美诺生物技术有限公司 检测慢性间质性肾炎的重组抗原的制备方法
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
CN114989287B (zh) * 2022-06-06 2024-04-09 孙英贤 脱乙酰化修饰的baf155蛋白及其制药用途
CN114920816B (zh) * 2022-06-06 2024-04-05 孙英贤 Baf155突变基因及其制药用途
WO2024023245A1 (en) * 2022-07-27 2024-02-01 Biocell Innovations Pte. Ltd. Production of cells and viral vectors
CN115747170B (zh) * 2022-08-29 2023-08-04 四川大学 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用
CN115820580A (zh) * 2022-08-31 2023-03-21 武汉爱博泰克生物科技有限公司 活性重组hTET2蛋白的表达及纯化方法
CN115558712B (zh) * 2022-09-22 2026-03-24 华中科技大学同济医学院附属协和医院 Fam177a1的新用途
CN115850512B (zh) * 2022-10-14 2025-11-07 江苏大学 一种用于靶向治疗肿瘤的重组融合蛋白及其制备方法
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN115976004B (zh) * 2022-12-27 2024-07-09 天津科技大学 一种黄体酮17α-羟化酶突变体及其应用
EP4652153A1 (en) 2023-01-20 2025-11-26 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
GB2626983A (en) * 2023-02-10 2024-08-14 Quell Therapeutics Ltd Protein
CN116253778B (zh) * 2023-03-03 2025-09-23 中山大学 一种缓解长春新碱致神经病理性疼痛的多肽及其应用
CN118109416B (zh) * 2023-03-30 2024-11-22 广州百吉生物制药有限公司 功能增强型工程化免疫细胞及其制备和应用
KR20250173518A (ko) 2023-04-05 2025-12-10 포세이다 테라퓨틱스, 인크. 트랜스포사제 폴리뉴클레오티드 및 그의 용도
CN121195063A (zh) 2023-04-05 2025-12-23 波西达治疗公司 嵌合转座酶及其用途
WO2024211512A2 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Transposases and uses thereof
CN116478271B (zh) * 2023-06-19 2023-08-29 青岛大学 半滑舌鳎抗病基因PPARα及其编码蛋白的应用
CN119320771A (zh) * 2023-07-17 2025-01-17 北京艺妙神州医药科技有限公司 用于敲除t细胞中的trac和b2m的试剂和方法
CN116948015B (zh) * 2023-07-18 2024-07-05 山西锦波生物医药股份有限公司 生物合成人体结构性材料xxii型胶原蛋白的方法
WO2025029930A1 (en) * 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
CN116854801A (zh) * 2023-08-21 2023-10-10 广东省人民医院 Hand1重组蛋白及其制备方法和在治疗扩张性心肌病药物中的应用
CN122055354A (zh) 2023-09-01 2026-05-15 波西达治疗公司 类脂质化合物及相关组合物和用途
WO2025055927A1 (en) * 2023-09-13 2025-03-20 Qihan Hong Kong Limited Immunotherapies using hypoimmunogenic engineered cells
IL327036A (en) 2023-09-19 2026-05-01 Poseida Therapeutics Inc Compositions and methods for combining viral vectors
CN117586418B (zh) * 2023-11-08 2025-07-15 东南大学 一种丝氨酸蛋白酶抑制剂及其应用
WO2025106376A1 (en) * 2023-11-17 2025-05-22 Dna Twopointo Inc. Mammalian cell lines for transient protein production
CN117551621B (zh) * 2023-11-20 2024-04-30 梅州市人民医院(梅州市医学科学院) 一种杂交瘤细胞株l008、单克隆抗体及其应用
CN117883382B (zh) * 2023-11-27 2025-02-14 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途
CN117820434B (zh) * 2023-12-31 2024-11-19 武汉优恩生物科技有限公司 牛羊妊娠相关糖蛋白的多肽抗原及应用
WO2025156492A1 (zh) * 2024-01-23 2025-07-31 星尘股份有限公司 转座酶及其用途
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
CN118146342B (zh) * 2024-02-06 2026-06-26 同济大学 一种Smad5突变体及在防治糖尿病中的应用
CN117919389B (zh) * 2024-03-22 2024-07-23 上海南方模式生物科技股份有限公司 肿瘤新抗原dna疫苗
CN118584109B (zh) * 2024-03-26 2025-08-15 首都医科大学附属北京胸科医院 一种筛选耐药性肺癌的生物标志物
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
CN118308420B (zh) * 2024-04-19 2025-06-03 东北农业大学 一种大豆基因Glyma.18G041900的应用
CN118360271B (zh) * 2024-05-07 2025-12-05 中国海洋大学 一种脂肪酶突变体及其在提升白酒酯类风味物质中的应用
CN118240829B (zh) * 2024-05-21 2024-07-23 华南农业大学 NompC基因在防治桔小实蝇中的应用
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies
KR102974148B1 (ko) 2024-10-31 2026-06-10 한국생산기술연구원 신규한 경화제 및 경화제 제조방법
WO2026107088A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Dual car constructs and methods of use
WO2026107078A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Chimeric antigen receptor compositions and methods of use
CN119736407A (zh) * 2024-12-27 2025-04-01 西北农林科技大学 一种提高动物生长速度和大小的stc2基因编码序列突变体的应用
CN119899820B (zh) * 2025-01-23 2026-04-03 深圳开悦生命科技有限公司 Dhx8融合蛋白及其制备方法
CN120209114B (zh) * 2025-03-07 2026-04-07 首都医科大学 一种含有penk蛋白的组合物及其应用
CN119874865B (zh) * 2025-03-11 2025-11-25 东北林业大学 一种溪荪ost48蛋白在植物促分蘖中的应用
CN120192430B (zh) * 2025-03-24 2025-08-22 安康市中心医院 一种基于硒修饰的心肌保护多肽及其制备方法与应用
CN119978086B (zh) * 2025-03-31 2025-10-17 中国农业大学 一种调控植物生长发育的蛋白质dap1及其编码基因和应用
CN120607598B (zh) * 2025-05-16 2026-02-27 安徽大学 人源先锋转录因子sox15 hmg结构域重组蛋白及其制备方法
CN120624647B (zh) * 2025-05-30 2026-04-03 山西省肿瘤医院 鼻咽癌诊断或预测的甲基化标志物组合及应用、试剂盒和计算机可读存储介质
CN120591344B (zh) * 2025-06-13 2026-04-03 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用
CN120757661B (zh) * 2025-07-04 2026-05-26 江南大学 一种PTPσ_Ig1-3融合蛋白及其制备方法和应用
CN121203036B (zh) * 2025-09-24 2026-06-09 北京多美康医药科技有限公司 一种重组型胶原蛋白iii+x及其制备方法和应用
CN121186348B (zh) * 2025-11-25 2026-02-24 北京大学人民医院 瓜氨酸化内凝集素-1多肽在制备类风湿关节炎诊断产品中的应用
CN121471381B (zh) * 2026-01-12 2026-05-08 南京医科大学 Tat-po1及其在治疗神经退行性疾病肌萎缩侧索硬化症中的应用
CN121538143B (zh) * 2026-01-20 2026-04-10 北京绿色康成生物技术有限公司 生产麦角硫因的重组微生物、重组表达载体及制备麦角硫因的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
AU2015312117A1 (en) * 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
AU2017248830B2 (en) * 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US11725210B2 (en) * 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
JP2020530997A (ja) * 2017-08-08 2020-11-05 サンガモ セラピューティクス, インコーポレイテッド キメラ抗原受容体媒介性細胞標的化
BR112020018049A2 (pt) * 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso

Similar Documents

Publication Publication Date Title
AU2017373815C1 (en) Novel T cell receptors and immune therapy using the same
TWI727182B (zh) 新型t細胞受體及其免疫治療
ES2989596T3 (es) Receptores que proporcionan coestimulación dirigida para terapia celular adoptiva
TWI775768B (zh) 新穎t細胞受器及使用其之免疫治療
JP2022130485A5 (enExample)
JP6985934B2 (ja) 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
JP2022550899A5 (enExample)
JP2021036883A5 (enExample)
CN110494160A (zh) T细胞受体及其针对prame阳性癌症的免疫治疗
KR102723492B1 (ko) 생체내 지속성 및 치료학적 활성 및 이의 증식을 위한 nkt-세포 서브세트
JP2021522790A5 (enExample)
CN110325205A (zh) T细胞调节性多聚体多肽及其使用方法
JP2021511041A5 (enExample)
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
JP2021502122A5 (enExample)
JP2018522567A (ja) 固形腫瘍を標的とする二重特異性car t細胞
CN105209065A (zh) 控制t细胞增殖的方法
JP2012507994A (ja) Hla−gタンパク質及びその薬学的使用
CA3042613A1 (en) Chimeric antigen receptor
JP2019535262A5 (enExample)
TWI875737B (zh) T細胞受體及其使用方法
JP2021536245A (ja) 血液中または濃縮pbmc中のリンパ球を遺伝子改変するための方法および組成物
JP2021526795A5 (enExample)
JP2019513394A5 (enExample)
US20240294875A1 (en) Reprogrammed T Cell-Like NK Cells